For example, women carrying pathogenic variants (PVs) in BRCA1 have a 55%–72% lifetime risk of developing breast cancer, 39%–44% lifetime risk of developing ovarian cancer; women carrying pathogenic variants in BRCA2 have a 45%–69% risk of developing breast cancer and 11%–17% lifetime risk of developing ovarian cancer [17–19]. The gene discussed is BRCA2; the disease is ovarian carcinoma.